{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:41:54Z","timestamp":1782456114881,"version":"3.54.5"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1 U50 CK000477"],"award-info":[{"award-number":["1 U50 CK000477"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Bacteremia in adult patients has traditionally been treated with extended courses of intravenous antibiotics. Data on the use of (or rapid transition to) oral therapy are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult infectious disease physicians participating in the Infectious Diseases Society of America Emerging Infections Network (EIN) were surveyed regarding their use of oral antibiotics in patients with bacteremia. Respondents were asked to assume that patients were hemodynamically stable, recovered bacteria were susceptible to potential antibiotics, adequate source control had been achieved, and patients had adequate gastrointestinal absorption. Variables of specific bacteria, oral agent, and associated infection were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 655 (50%) of 1321 EIN participants responded. Under certain conditions, 88% would transition patients with Gram-negative bacteremia to complete a course of therapy with oral antibiotics; 71% would transition patients with Gram-positive bacteremia to oral agents. Only 78 (12%) respondents would not treat any bacteremic patient with oral agents. Most respondents (\u226575%) were comfortable treating infections secondary to Enterobacteriaceae, Salmonella, Pseudomonas, Stenotrophomonas, Streptococcus pneumoniae, and \u03b2-hemolytic streptococci with oral agents. Fewer than 20% endorsed use of oral antibiotics for Staphylococcus aureus or in cases of endocarditis. Fluoroquinolones and trimethoprim-sulfamethoxazole were the preferred agents in Gram-negative bacteremia; linezolid and \u03b2-lactams were the preferred agents in Gram-positive bacteremia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In select circumstances, the majority of respondents would transition patients to oral antibiotics, in both Gram-negative and Gram-positive bacteremia. Most agreed with the use of oral agents in Gram-negative bacteremia caused by Enterobacteriaceae, but they would not use oral agents for Gram-positive bacteremia caused by S aureus or in endocarditis.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ofid\/ofz386","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T18:17:20Z","timestamp":1567189040000},"source":"Crossref","is-referenced-by-count":39,"title":["Practice Patterns of Infectious Diseases Physicians in Transitioning From Intravenous to Oral Therapy in Patients With Bacteremia"],"prefix":"10.1093","volume":"7","author":[{"given":"Duane R","family":"Hospenthal","sequence":"first","affiliation":[{"name":"San Antonio Infectious Diseases Consultants, San Antonio, Texas"},{"name":"University of Texas Health Sciences Center at San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Dustin","family":"Waters","sequence":"additional","affiliation":[{"name":"Intermountain Healthcare McKay-Dee Hospital, Ogden, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E","family":"Beekmann","sequence":"additional","affiliation":[{"name":"Emerging Infections Network, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M","family":"Polgreen","sequence":"additional","affiliation":[{"name":"Emerging Infections Network, University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"2020122901395115800_CIT0001","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/cid\/cit932","article-title":"The Infectious Diseases Society of America Emerging Infections Network: bridging the gap between clinical infectious diseases and public health","volume":"58","author":"Pillai","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020122901395115800_CIT0002","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with Enterobacteriaceae bacteremia","author":"Tamma","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2020122901395115800_CIT0003","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ijantimicag.2017.12.007","article-title":"Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: fluoroquinolones versus \u03b2-lactams","volume":"51","author":"Mercuro","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020122901395115800_CIT0004","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/phar.2024","article-title":"Intravenous-only or intravenous transitioned to oral antimicrobials for Enterobacteriaceae-associated bacteremic urinary tract infection","volume":"37","author":"Rieger","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2020122901395115800_CIT0005","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijantimicag.2016.07.013","article-title":"Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections","volume":"48","author":"Kutob","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2020122901395115800_CIT0006","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/1078155215591389","article-title":"Outcomes of hospitalized neutropenic oncology patients with Pseudomonas aeruginosa bloodstream infections: focus on oral fluoroquinolone conversion","volume":"22","author":"Yan","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"2020122901395115800_CIT0007","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1007\/s10620-014-3233-0","article-title":"Early oral antibiotic switch compared with conventional intravenous antibiotic therapy for acute cholangitis with bacteremia","volume":"59","author":"Park","year":"2014","journal-title":"Dig Dis Sci"},{"key":"2020122901395115800_CIT0008","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/jac\/dkt177","article-title":"Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection\u2013 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials","volume":"68","author":"Eliakim-Raz","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020122901395115800_CIT0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","article-title":"A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400\/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"71","author":"Peterson","year":"2008","journal-title":"Urology"},{"key":"2020122901395115800_CIT0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archinte.159.1.53","article-title":"Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial","volume":"159","author":"Mombelli","year":"1999","journal-title":"Arch Intern Med"},{"key":"2020122901395115800_CIT0011","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/cid\/cix767","article-title":"Comparing the outcomes of adults with enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort","volume":"66","author":"Chotiprasitsakul","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020122901395115800_CIT0012","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020122901395115800_CIT0013","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/bmj.38993.560984.BE","article-title":"Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial","volume":"333","author":"Oosterheert","year":"2006","journal-title":"BMJ"},{"key":"2020122901395115800_CIT0014","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/archinte.161.6.848","article-title":"Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia","volume":"161","author":"Ramirez","year":"2001","journal-title":"Arch Intern Med"},{"key":"2020122901395115800_CIT0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"2020122901395115800_CIT0016","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cmi.2016.04.003","article-title":"Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients","volume":"22","author":"Mzabi","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2020122901395115800_CIT0017","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s10096-016-2661-5","article-title":"Effectiveness of sequential intravenous-to-oral antibiotic switch therapy in hospitalized patients with Gram-positive infection: the SEQUENCE cohort study","volume":"35","author":"Rodriguez-Pardo","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020122901395115800_CIT0018","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jac\/dky452","article-title":"Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer","volume":"74","author":"Jorgensen","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020122901395115800_CIT0019","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2334-14-140","article-title":"Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review","volume":"14","author":"Al-Omari","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2020122901395115800_CIT0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9343(96)00070-8","article-title":"Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy","volume":"101","author":"Heldman","year":"1996","journal-title":"Am J Med"},{"key":"2020122901395115800_CIT0021","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(89)91083-0","article-title":"Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin","volume":"2","author":"Dworkin","year":"1989","journal-title":"Lancet"},{"key":"2020122901395115800_CIT0022","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2016.06.010","article-title":"Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis","volume":"48","author":"Zhao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2020122901395115800_CIT0023","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/civ444","article-title":"Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a National Cohort Study of Veterans Affairs Patients","volume":"61","author":"Britt","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020122901395115800_CIT0024","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020122901395115800_CIT0025","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020122901395115800_CIT0026","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy916","article-title":"Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study","author":"Willekens","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020122901395115800_CIT0027","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1469-0691.12195","article-title":"Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe","volume":"19","author":"Goto","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2020122901395115800_CIT0028","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s15010-017-0997-0","article-title":"The \u201cChoosing Wisely\u201d initiative in infectious diseases","volume":"45","author":"Lehmann","year":"2017","journal-title":"Infection"},{"key":"2020122901395115800_CIT0029","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijantimicag.2017.12.010","article-title":"Management of bloodstream infections by infection specialists: an international ESCMID cross-sectional survey","volume":"51","author":"Diallo","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020122901395115800_CIT0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-018-1122-8","article-title":"Management of bloodstream infections by infection specialists in France and Germany: a cross-sectional survey","volume":"46","author":"Diallo","year":"2018","journal-title":"Infection"},{"key":"2020122901395115800_CIT0031","doi-asserted-by":"crossref","first-page":"328","DOI":"10.12788\/jhm.2949","article-title":"When are oral antibiotics a safe and effective choice for bacterial bloodstream infections? An evidence-based narrative review","volume":"13","author":"Hale","year":"2018","journal-title":"J Hosp Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofz386\/30078950\/ofz386.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/12\/ofz386\/35225171\/ofz386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/12\/ofz386\/35225171\/ofz386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:49:07Z","timestamp":1664239747000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz386\/5556891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz386","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2019,8,30]]},"article-number":"ofz386"}}